期刊文献+

尿肌氨酸水平对前列腺癌诊断及预后判断的应用价值 被引量:1

Diagnostic and prognostic value of urinary sarcosine for prostatic cancer
下载PDF
导出
摘要 目的探讨尿肌氨酸水平对前列腺癌(PCa)的诊断和病情判断方面的应用价值。方法选取我院泌尿外科住院的经前列腺穿刺活检确诊的PCa患者16例,年龄65±89(68.4±10.2)岁。采集PCa患者的血标本和尿标本,然后用同位素稀释液相色谱质谱法检测其血、尿肌氨酸水平,电化学发光法检测血清前列腺特异抗原(PSA)水平,并根据其Gleason评分及是否骨转移进行统计学分析。结果PCa伴有骨转移患者(n=9)与无转移患者(n=7)血清总前列腺持异抗原(TPSA)水平含量差异具有统计学意义[(203.95±169.68)w(35.53±35.77)pg/L,P〈O.05],而游离前列腺持异抗原(fPSA)水平在两组间差异无统计学意义[(14.41±11.84)VS(3.92±4.15)μg/L]。PCa伴有骨转移患者的尿液中肌氨酸含量明显高于不伴发骨转移患者[(1277.67±432.78)VS(494.71±211.35)μg/L,P=O.018]。按照Pca病理结果分级,血肌氨酸水平在各个Gleason评分组中差异无统计学意义;而尿肌氨酸含量差异具有统计学意义(P〈0.015),且Gleason评分越高,尿液中肌氨酸含量也越高。PCa患者的尿肌氨酸水平与Gleason评分及是否骨转移具有相关性,且组间差异具有统计学意义(P〈0.05)。结论尿肌氨酸有可能成为用于诊断PCa的肿瘤标志物,并具有一定的判断病情的应用价值。 Objective To investigate the value of the urinary sarcosine in the diagnosis and prognosis of prostate cancer(PCa). Methods A total of 16 PCa patients, with age ranging from 65 to 89(68.4± 10.2)years, diagnosed by prostate biopsy in our department from May 2009 to May 2011, were enrolled in this study. Their blood and urinary samples were collected for detection of sarcosine level by isotope dilution-liquid chromatography mass spectrometry (LC/MS). Electrochemiluminescence assay was used for the detection of serum level of prostate specific antigen (PSA). The results were statistically analyzed with their Gleason scores and with bone metastasis. Results There was significant difference in the total PSA(TPSA) level between the PCa patients with bone metastases In = 9, (203.95 ± 169.68)ktg/L] and without In = 7, (35.53 ± 35.77)μg/L, P〈 0.05], while no difference was found in free PSA (fPSA) level between them [(14.41 ±11.84) vs (3.92 ±4.15)μg/L, P〉 0.05]. The urinary sarcosine level was significantly higher in the PCa patients with bone metastasis than those without [(1277.67± 432.78) vs (494.71 ± 211.35) μg/L, P= 0.018]. There was no significant difference in the serum sarcosine level between different pathological Gleason scores, but urinary sarcosine level was significantly elevated with the increase of Gleason score(P 〉 0.05). Urinary sarcosin level was correlated with Gleason score and bone metastasis(P 〈 0.05). Conelusion Urinary sarcosine might be used as a useful tumor marker for the diagnosis and prognosis of PCa.
出处 《中华老年多器官疾病杂志》 2013年第11期823-825,共3页 Chinese Journal of Multiple Organ Diseases in the Elderly
关键词 前列腺癌 尿肌氨酸 质谱分析法 prostate cancer urinary sarcosine mass spectrometry
  • 相关文献

参考文献9

  • 1Cavaliere B, Macchione B, Monteleone M, et al. Sarcosine as a marker in prostate cancer progression: a rapid and simple method for its quantification in human urine by solid-phase microextraction-gas chromatography-triple quadrupole mass spectrometry[J]. Anal Bioanal Chem, 2011, 400(9): 2903-2912.
  • 2Cilja H, Chritensson A, Dahlen U, et al. Prostate specific antigen in serum occurs predominantly in complex with alpha 1 antichymotrypsin[J]. Clin Chem, 1991, 37(9): 1618-1625.
  • 3Rifkin MD. Ultrasound of the prostate: imaging in the diagnosis and therapy of prostate disease[M]. 2nd Edition. Philadelphia. New York: Lippincott-Raven Publishers,1997: 48-50.
  • 4Kalish J, Conner WH, Graham SD. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume(PSAD) in detecting adenocarcinoma of the prostate[J]. Urology, 1994, 43(5): 601-606.
  • 5Catalona WJ, Partin AW, Slawin KM. Use of the percentage of free prostatic specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multi-center clinical trial[J]. JAMA, 1998, 279(34): 1542-1547.
  • 6Kamoi K, Babaian RJ. Advances in the application of prostate specific antigen in the detection of early stage prostate cancer[J]. Sere Oncol, 1999, 26(3): 140-149.
  • 7Thompson IM, Ankerst DR Prostate specific antigen in the early detection of prostate cancer[J]. CMAJ, 2007, 176(13): 1853-1858.
  • 8Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sareosine in prostate cancer progression[J]. Nature, 2009, 457(7231): 910-914.
  • 9Bohm L, Serafin AM, Fernandez P, et al. Plasma sarcosine does not distinguish early and advanced stages of prostate cancer[J]. Resarch, 2012, 102(8): 677-679.

同被引文献8

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部